company background image
LNSR

LENSAR NasdaqCM:LNSR Stock Report

Last Price

US$6.46

Market Cap

US$71.0m

7D

0.9%

1Y

-21.9%

Updated

06 Jul, 2022

Data

Company Financials +
LNSR fundamental analysis
Snowflake Score
Valuation3/6
Future Growth2/6
Past Performance0/6
Financial Health6/6
Dividends0/6

LNSR Stock Overview

LENSAR, Inc., a commercial-stage medical device company, focuses on designing, developing, and marketing a femtosecond laser system for the treatment of cataracts and the management of pre-existing or surgically induced corneal astigmatism.

LENSAR Competitors

Price History & Performance

Summary of all time highs, changes and price drops for LENSAR
Historical stock prices
Current Share PriceUS$6.46
52 Week HighUS$8.98
52 Week LowUS$5.50
Beta0
1 Month Change-0.62%
3 Month Change-10.40%
1 Year Change-21.89%
3 Year Changen/a
5 Year Changen/a
Change since IPO-28.22%

Recent News & Updates

Shareholder Returns

LNSRUS Medical EquipmentUS Market
7D0.9%2.0%0.3%
1Y-21.9%-24.9%-18.4%

Return vs Industry: LNSR exceeded the US Medical Equipment industry which returned -24.9% over the past year.

Return vs Market: LNSR underperformed the US Market which returned -18.4% over the past year.

Price Volatility

Is LNSR's price volatile compared to industry and market?
LNSR volatility
LNSR Average Weekly Movement5.6%
Medical Equipment Industry Average Movement10.4%
Market Average Movement8.1%
10% most volatile stocks in US Market16.8%
10% least volatile stocks in US Market3.3%

Stable Share Price: LNSR is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 6% a week.

Volatility Over Time: LNSR's weekly volatility (6%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
2004110Nick Curtishttps://www.lensar.com

LENSAR, Inc., a commercial-stage medical device company, focuses on designing, developing, and marketing a femtosecond laser system for the treatment of cataracts and the management of pre-existing or surgically induced corneal astigmatism. Its LENSAR Laser System incorporates a range of proprietary technologies designed to assist the surgeon in obtaining visual outcomes, efficiency, and reproducibility by providing imaging, procedure planning, design, and precision. The company was incorporated in 2004 and is headquartered in Orlando, Florida.

LENSAR Fundamentals Summary

How do LENSAR's earnings and revenue compare to its market cap?
LNSR fundamental statistics
Market CapUS$70.96m
Earnings (TTM)-US$21.09m
Revenue (TTM)US$36.76m

1.9x

P/S Ratio

-3.4x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
LNSR income statement (TTM)
RevenueUS$36.76m
Cost of RevenueUS$18.13m
Gross ProfitUS$18.63m
Other ExpensesUS$39.72m
Earnings-US$21.09m

Last Reported Earnings

Mar 31, 2022

Next Earnings Date

n/a

Earnings per share (EPS)-1.92
Gross Margin50.69%
Net Profit Margin-57.39%
Debt/Equity Ratio0%

How did LNSR perform over the long term?

See historical performance and comparison
We’ve recently updated our valuation analysis.

Valuation

Is LNSR undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

3/6

Valuation Score 3/6

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Below Fair Value

  • Significantly Below Fair Value

  • PEG Ratio

Key Valuation Metric

Which metric is best to use when looking at relative valuation for LNSR?

Other financial metrics that can be useful for relative valuation.

LNSR key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue1.2x
Enterprise Value/EBITDA-2.3x
PEG Ration/a

Price to Sales Ratio vs Peers

How does LNSR's PS Ratio compare to its peers?

LNSR PS Ratio vs Peers
The above table shows the PS ratio for LNSR vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyPSEstimated GrowthMarket Cap
Peer Average2.6x
UTRS Minerva Surgical
1.3x24.7%US$68.0m
MLSS Milestone Scientific
7.9x18.7%US$71.9m
LHDX Lucira Health
0.5x11.9%US$77.3m
VAPO Vapotherm
0.7x13.2%US$69.3m
LNSR LENSAR
1.9x21.2%US$70.0m

Price-To-Sales vs Peers: LNSR is good value based on its Price-To-Sales Ratio (1.9x) compared to the peer average (2.4x).


Price to Earnings Ratio vs Industry

How does LNSR's PE Ratio compare vs other companies in the US Medical Equipment Industry?

Price-To-Sales vs Industry: LNSR is good value based on its Price-To-Sales Ratio (1.9x) compared to the US Medical Equipment industry average (4x)


Price to Sales Ratio vs Fair Ratio

What is LNSR's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

LNSR PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio1.9x
Fair PS Ratio2.4x

Price-To-Sales vs Fair Ratio: LNSR is good value based on its Price-To-Sales Ratio (1.9x) compared to the estimated Fair Price-To-Sales Ratio (2.4x).


Share Price vs Fair Value

What is the Fair Price of LNSR when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate LNSR's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate LNSR's fair value for valuation analysis.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate LNSR's PEG Ratio to determine if it is good value.


Discover undervalued companies

Future Growth

How is LENSAR forecast to perform in the next 1 to 3 years based on estimates from 1 analyst?

Future Growth Score

2/6

Future Growth Score 2/6

  • Earnings vs Savings Rate

  • Earnings vs Market

  • High Growth Earnings

  • Revenue vs Market

  • High Growth Revenue

  • Future ROE


8.5%

Forecasted annual earnings growth

Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: LNSR is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: LNSR is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: LNSR is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: LNSR's revenue (21.2% per year) is forecast to grow faster than the US market (7.9% per year).

High Growth Revenue: LNSR's revenue (21.2% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if LNSR's Return on Equity is forecast to be high in 3 years time


Discover growth companies

Past Performance

How has LENSAR performed over the past 5 years?

Past Performance Score

0/6

Past Performance Score 0/6

  • Quality Earnings

  • Growing Profit Margin

  • Earnings Trend

  • Accelerating Growth

  • Earnings vs Industry

  • High ROE


-15.5%

Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: LNSR is currently unprofitable.

Growing Profit Margin: LNSR is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: LNSR is unprofitable, and losses have increased over the past 5 years at a rate of 15.5% per year.

Accelerating Growth: Unable to compare LNSR's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: LNSR is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (12.9%).


Return on Equity

High ROE: LNSR has a negative Return on Equity (-42.35%), as it is currently unprofitable.


Discover strong past performing companies

Financial Health

How is LENSAR's financial position?

Financial Health Score

6/6

Financial Health Score 6/6

  • Short Term Liabilities

  • Long Term Liabilities

  • Debt Level

  • Reducing Debt

  • Stable Cash Runway

  • Forecast Cash Runway

Financial Position Analysis

Short Term Liabilities: LNSR's short term assets ($38.6M) exceed its short term liabilities ($7.8M).

Long Term Liabilities: LNSR's short term assets ($38.6M) exceed its long term liabilities ($2.7M).


Debt to Equity History and Analysis

Debt Level: LNSR is debt free.

Reducing Debt: LNSR had no debt 5 years ago.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: LNSR has sufficient cash runway for more than 3 years based on its current free cash flow.

Forecast Cash Runway: LNSR has sufficient cash runway for 2.6 years if free cash flow continues to grow at historical rates of 9.5% each year.


Discover healthy companies

Dividend

What is LENSAR current dividend yield, its reliability and sustainability?

Dividend Score

0/6

Dividend Score 0/6

  • Notable Dividend

  • High Dividend

  • Stable Dividend

  • Growing Dividend

  • Earnings Coverage

  • Cash Flow Coverage

Dividend Yield vs Market

Notable Dividend: Unable to evaluate LNSR's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate LNSR's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if LNSR's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if LNSR's dividend payments have been increasing.


Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as LNSR has not reported any payouts.


Discover strong dividend paying companies

Management

How experienced are the management team and are they aligned to shareholders interests?

4.7yrs

Average management tenure


CEO

Nick Curtis (66 yo)

10.42yrs

Tenure

US$1,324,440

Compensation

Mr. Nicholas T. Curtis serves as the Chief Executive Officer and Director of LensAR Inc since February 2012. Mr. Curtis served as the Chief Commercial Officer of LensAR Inc. from August 2010 until February...


CEO Compensation Analysis

Compensation vs Market: Nick's total compensation ($USD1.32M) is above average for companies of similar size in the US market ($USD787.63K).

Compensation vs Earnings: Nick's compensation has been consistent with company performance over the past year.


Leadership Team

Experienced Management: LNSR's management team is considered experienced (4.7 years average tenure).


Board Members

Experienced Board: LNSR's board of directors are considered experienced (4.4 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

LENSAR, Inc.'s employee growth, exchange listings and data sources


Key Information

  • Name: LENSAR, Inc.
  • Ticker: LNSR
  • Exchange: NasdaqCM
  • Founded: 2004
  • Industry: Health Care Equipment
  • Sector: Healthcare
  • Implied Market Cap: US$70.962m
  • Shares outstanding: 10.98m
  • Website: https://www.lensar.com

Number of Employees


Location

  • LENSAR, Inc.
  • 2800 Discovery Drive
  • Orlando
  • Florida
  • 32826
  • United States

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/07/06 00:00
End of Day Share Price2022/07/06 00:00
Earnings2022/03/31
Annual Earnings2021/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.